The launch of the Retatru vial marks a notable shift in the approach to weight regulation. This novel drug combines two mechanisms – activation of the GLP-1 site and blocking of the DPP-4 factor – providing a distinctive method for managing obesity . Early research results indicate promising results in promoting considerable weight decline and